Company
Headquarters: Wuhan, China
Employees: 2,004
CN¥6.46 Billion
CNY as of Jan. 1, 2025
US$885.7 Million
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Jianmin Pharmaceutical Group Co.,Ltd. manufactures and sells Chinese medicines in China. It offers pediatric drugs under the Jianmin and Longmu brands. The company also provides OTC, medical, and health products, as well as consultation service. Jianmin Pharmaceutical Group Co.,Ltd. is headquartered in Wuhan, China.
| Last Financial Reports Date | Sept. 30, 2024 |
| Revenue TTM | CN¥3.98 B |
| EBITDA | CN¥490.7 M |
| Gross Profit TTM | CN¥1.70 B |
| Profit Margin | 10.76% |
| Operating Margin | 2.89% |
| Quarterly Revenue Growth | -8.80% |
Jianmin Pharmaceutical Group Co. Ltd has the following listings and related stock indices.
Stock: SSE: 600976 wb_incandescent